A new antibiotic compound clears infection of multi-drug resistant gonorrhea in mice in a single oral dose, according to a new study. The compound targets a molecular pathway found in bacteria but not humans and could lead to new treatments for gonorrhea and infections from other bacteria, such as tuberculosis and MRSA.
The researchers published their results in a paper in the journal Nature Communications.
Gonorrhea infects more than 500 thousand people in the United States each year, and several strains of the bacteria that causes the disease, Neisseria gonorrhoeae, are resistant to multiple antibiotics in use today. For this reason, the Centers for Disease Control and Prevention (CDC) lists multi-drug resistant gonorrhea as one of the five most dangerous urgent threats today.
"Many current antibiotics target the process of translation--when proteins are made based on information in genetic material--within the bacteria," said an author of the paper. "Over the last decade, we have been investigating a family of compounds that instead inhibit the trans-translation pathway in bacteria, which bacteria use to fix certain kinds of errors during protein synthesis. In this paper, we provide a proof-of-concept that inhibiting the trans-translation pathway can effectively clear multi-drug resistant gonorrhea in animals."
The researchers previously identified a promising trans-translation inhibitor that clears gonorrhea infection in lab cultures but is ineffective in animals because the compound breaks down. In this study, members of the research team at Microbiotix strategically altered the compound to identify which portions of its structure were necessary to inhibit the pathway and which could be changed to improve its stability.
"Our iterative optimization campaign evaluated over 500 versions of the compound to assess their potency, toxicity, and other pharmacological properties," said another author of the paper. "We determined that the central region of the compound plays a critical role in blocking the trans-translation pathway, however modifications at the periphery could be altered to modulate its pharmacological properties. By altering a functional group to sidestep the primary mechanism of metabolism, we can create versions of the compound that are much more stable in animals."
Members of the research team then tested one of these modified compounds, MBX-4132, in mice. Their experiments utilized the gonorrhea strain WHO-X, an extremely virulent pathogen that is resistant to almost all approved antibiotics. A single oral dose of the compound completely cleared the infection in 80% of mice within six days, and the bacterial load in the remaining 20% was dramatically reduced.
"Developing a single dose therapy for gonorrhea is incredibly important," said the author. "In some cases, bacteria can develop resistance to a drug when additional doses are skipped, for example when a patient starts to feel better and stops taking antibiotics. With a single dose therapy, a patient could complete the treatment during a visit to their health provider."
To better determine how the compound inhibits the trans-translation pathway, members of the research team used cryo-electron microscopy (cryo-EM) to produce high-resolution images of the compound as it binds to the bacterial ribosome--the macromolecule where proteins are synthesized.
"A derivative of MBX-4132 binds to a location on the ribosome that is different from all known antibiotic binding sites," said another author of the paper. "The new drug also displaces a region of a ribosomal protein that we think could be important during the normal process of trans-translation. Because trans-translation only occurs in bacteria and not in humans, we hope that the likelihood of the compound affecting protein synthesis in humans is greatly reduced, a hypothesis strongly supported by the safety and selectivity studies performed by Microbiotix."
The research team plans to further optimize the compound before pursuing preclinical trials.
"This type of compound is actually a broad-spectrum inhibitor," said the author. "It is effective against most Gram-positive bacteria--including tuberculosis and difficult-to-treat staph infections (MRSA)--and some Gram-negative bacteria and could be a promising candidate for future treatments. In this study, we lay the groundwork for using this type of compound and demonstrate that inhibiting the trans-translation pathway in bacteria is a viable antibiotic strategy."
https://www.nature.com/articles/s41467-021-22012-7
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Ftrans-translation&filter=22
New antibiotic clears multi-drug resistant gonorrhea in mice in single dose
- 1,402 views
- Added
Edited
Latest News
How antisense non-coding RN…
By newseditor
Posted 07 Jul
3D maps of diseased tissues…
By newseditor
Posted 06 Jul
How GLP-1 receptor agonists…
By newseditor
Posted 06 Jul
Pan-cancer proteogenomics e…
By newseditor
Posted 05 Jul
Fertility treatments could…
By newseditor
Posted 05 Jul
Other Top Stories
Molecule regulating sperm motility discovered
Read more
Cellular motion to help wound healing
Read more
Protein synthesis in thin film organelles
Read more
Stabilizing CAG repeat expansion in Huntington's disease
Read more
Human embryonic development at the single cell level!
Read more
Protocols
Pan-cancer proteogenomics c…
By newseditor
Posted 05 Jul
A systems biology-based ide…
By newseditor
Posted 05 Jul
Tongue orthotopic xenograft…
By newseditor
Posted 04 Jul
Monitoring norepinephrine r…
By newseditor
Posted 01 Jul
BicemuS: A new tool for neu…
By newseditor
Posted 26 Jun
Publications
dsRNA formation leads to pr…
By newseditor
Posted 07 Jul
BACH1 inhibits senescence,…
By newseditor
Posted 07 Jul
Bone transport induces the…
By newseditor
Posted 06 Jul
Hypothalamic neuronal activ…
By newseditor
Posted 06 Jul
Prevention of Falls in Olde…
By newseditor
Posted 05 Jul
Presentations
Myelin plasticity in the ve…
By newseditor
Posted 10 Jun
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar